Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 with Pemetrexed and Cisplatin in Advanced Tumors
NCT02029690Phase 1Terminated
- Sponsor
- Polaris Group
- Start
- Apr 2014
- Primary completion
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of Pegargiminase in malignant pleural mesothelioma (MPM), peritoneal mesothelioma, non-small cell lung carcinoma (NSCLC) and 4 more, sponsored by Polaris Group. Primary endpoints: Initial estimates of efficacy measured by RECIST 1.1 criteria at 18 weeks and Initial estimates of efficacy measured by modified RECIST criteria at 18 weeks. Started Apr 2014; status: terminated.
02
Drugs
Pegargiminase
03
Conditions
malignant pleural mesothelioma (MPM)peritoneal mesotheliomanon-small cell lung carcinoma (NSCLC)Uveal melanoma (UM)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02029690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02029690.